In patient-derived SCLC organoids, a combination strategy employing dual TIGIT/VSIG4 blockade alongside the ATR inhibitor AZD6738 tripled the intratumoral CD8+ T cell/Treg ratio (n=5; p=0.004), highlighting the potential of co-targeting these nodes (55). Here, CD8A is linked to small cell lung carcinoma.